|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-3-3
|
|
pubmed:abstractText |
Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity. A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's disease. We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AsselinBarbara LBL,
pubmed-author:AthaleUma HUH,
pubmed-author:BarryElly VEV,
pubmed-author:ClavellLuis ALA,
pubmed-author:CohenHarvey JHJ,
pubmed-author:DahlbergSuzanne ESE,
pubmed-author:LarsenEric CEC,
pubmed-author:LipshultzSteven ESE,
pubmed-author:MoghrabiAlbertA,
pubmed-author:NeubergDonna SDS,
pubmed-author:SallanStephen ESE,
pubmed-author:SamsonYvanY,
pubmed-author:SchorinMarshall AMA,
pubmed-author:SilvermanLewis BLB,
pubmed-author:VroomanLynda MLM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1106-11
|
|
pubmed:meshHeading |
pubmed-meshheading:18309945-Adolescent,
pubmed-meshheading:18309945-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18309945-Child,
pubmed-meshheading:18309945-Child, Preschool,
pubmed-meshheading:18309945-Disease-Free Survival,
pubmed-meshheading:18309945-Doxorubicin,
pubmed-meshheading:18309945-Female,
pubmed-meshheading:18309945-Follow-Up Studies,
pubmed-meshheading:18309945-Hodgkin Disease,
pubmed-meshheading:18309945-Humans,
pubmed-meshheading:18309945-Incidence,
pubmed-meshheading:18309945-Infant,
pubmed-meshheading:18309945-Infant, Newborn,
pubmed-meshheading:18309945-Male,
pubmed-meshheading:18309945-Neoplasms, Second Primary,
pubmed-meshheading:18309945-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:18309945-Razoxane,
pubmed-meshheading:18309945-Survival Rate
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
|
|
pubmed:affiliation |
Departments of Pediatric Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA. elly_barry@dfci.harvard.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Research Support, N.I.H., Extramural
|
